LogicBio Therapeutics, Inc. Common Stock
LOGC
LOGC was delisted on the 15th of November, 2022.
51 hedge funds and large institutions have $97.5M invested in LogicBio Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
19% more funds holding
Funds holding: 43 → 51 (+8)
0% less capital invested
Capital invested by funds: $97.7M → $97.5M (-$207K)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$392K |
| 2 |
JG
Jefferies Group
New York
|
+$258K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$209K |
| 4 |
BlackRock
New York
|
+$164K |
| 5 |
Millennium Management
New York
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.77M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$334K |
| 3 |
JP Morgan Chase
New York
|
-$317K |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$111K |
| 5 |
SC
Samlyn Capital
New York
|
-$99.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Adage Capital Partners
Boston,
Massachusetts
| – | -$6.77M | -800,000 | Closed |
|
|
52
First Trust Advisors
Wheaton,
Illinois
| – | -$111K | -13,110 | Closed |
|
|
SO
53
STRS Ohio
Columbus,
Ohio
| – | -$18K | -2,200 | Closed |
|
LOGC Hedge Fund Activity: Q3 2020 in Review
51 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2020, worth a combined $97.5M — down 0.21% from $97.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LOGC positions and 3 closed out — a net gain of 8 holders — while 14 added to existing stakes and 15 trimmed.
The largest buyer was Jacobs Levy Equity Management, adding an estimated $392K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $6.77M sold.
- 51 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2020, up from 43 in Q2 2020.
- Funds reported $97.5M of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2020, down 0.21% quarter-over-quarter.
- 11 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2020 and 3 closed out, a net change of +8 holders.
- The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2020 was Jacobs Levy Equity Management, an estimated $392K added.
- The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2020 was Adage Capital Partners, an estimated $6.77M sold.
Based on aggregated 13F filings for Q3 2020.